lipoprotein-associated phospholipase A2 (Lp-PLA2) in serum/plasma
Jump to navigation
Jump to search
Indications
- cardiovascular risk assessment
- risk for coronary artery disease
- may be screening test of choice to predict cardiovascular risk in black women[3]
Clinical significance
- increased levels associated with increased risk of coronary artery disease
Additional terms
References
- ↑ Teitz Textbook of Clinical Chemistry and Molecular Diagnostics, 4th edition, Burtis CA, Ashwood ER, Burns DE (eds), Elsevier, St Louis, 2006
- ↑ Lipoprotein-Associated Phospholipase A2 Laboratory Test Directory ARUP: http://www.aruplab.com/guides/ug/tests/0081055.jsp
Lp-PLA2, Lipoprotein-Associated Phospholipase A2, Activity (PLAC) Laboratory Test Directory ARUP: http://www.aruplab.com/guides/ug/tests/0000000.jsp - ↑ 3.0 3.1 Young K, Fairchild DG, Di Francesco L FDA Clears Test to Help Predict Coronary Heart Disease Risk Physician's First Watch, Dec 17, 2014 David G. Fairchild, MD, MPH, Editor-in-Chief Massachusetts Medical Society http://www.jwatch.org
FDA News Release. December 15, 2014 FDA clears test that helps predict the risk of coronary heart disease. Study data show test predicts risk better in black women. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm426799.htm